NCT04693897

Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and as a Urinary Biomarker

To Explore the Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and Develop Its Urinary Biomarker

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 400 (estimated)
• Sponsor: Chang Gung Memorial Hospital · Academic / Other
• Sex: Female
• Age: —
• Healthy volunteers: Accepted

Summary

About one to two million women in Taiwan suffers from overactive bladder (OAB). The most commonly used anti-muscarinic drugs have a high rate of side effects. While beta-3 adrenoceptor agonist, Mirabegron, has far fewer side effects, there are no consensus on whether it can be used as first-line treatment. The investigator's preliminary study showed that the concentration of beta-3 adrenoceptor in the urine of OAB patients is higher than that in the normal control group, so comparing urinary beta-3 adrenoceptor concentration of OAB patients before and after treatment may be used as a biomarker of therapeutic effectiveness. The results of this study will be of great help in understanding the effectiveness of Mirabegron and formulating OAB treatment plans.

Conditions

• Overactive Bladder Syndrome
• Detrusor Overactivity

Interventions

Type	Name	Description
DRUG	Mirabegron 50 MG	Mirabegron 50mg once daily given to treatment in patients with overactive bladder syndrome
DRUG	Solifenacin Succinate 5 MG	Solifenacin 5mg once daily given to treatment in patients with overactive bladder syndrome

Timeline

• Start date: 2021-03-01
• Primary completion: 2022-12-31
• Completion: 2022-12-31
• First posted: 2021-01-05
• Last updated: 2021-01-27

Regulatory

• FDA-regulated drug study